Recent 8-K filings for BHVN

• May 27, 2026, 5:13 PM ET other material materiality 0.95 positive item 7.01item 9.01

  Biohaven reports positive clinical data for opakalim in epilepsy and BHV-1300/BHV-1400 in autoimmune diseases at R&D Day

  Opakalim 75 mg prolonged median time to second seizure to 141 days vs 47 days for placebo in idiopathic generalized epilepsy trial.

• May 5, 2026, 7:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  Biohaven establishes $350M at-the-market equity offering via amended agreement with J.P. Morgan

  Amendment No. 2 to Equity Distribution Agreement allows up to $350M in common share sales.

• May 4, 2026, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Biohaven Q1 net loss $130.5M; pivotal epilepsy & obesity data due 2H 2026

  Net loss $130.5M ($0.88/sh) vs $221.7M ($2.17/sh) in Q1 2025; non-GAAP adjusted loss $102.2M ($0.69/sh).

• March 2, 2026, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Biohaven reports Q4 loss $145.6M, prioritizes three late-stage programs, raises $178.9M

  Q4 net loss $145.6M ($1.21/sh); non-GAAP adj. net loss $107.9M ($0.90/sh).

• January 7, 2026, 6:59 PM ET other material materiality 0.70 neutral item 8.01

  Biohaven to issue 12.5M shares at $10 each to Janus Henderson, raising $125M gross

  12,500,000 common shares at $10.00 per share, $125M gross proceeds expected.

• November 13, 2025, 6:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  Biohaven closes $200M public offering of 26.8M shares at $7.50/share

  Gross proceeds of approximately $200M from 26,833,334 common shares, including full exercise of underwriters' 3.5M share option.

• November 10, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Biohaven reports Q3 net loss $173.4M, plans 60% R&D spend cut to focus on three late-stage programs

  Net loss $173.4M ($1.64/share) vs $160.3M ($1.70/share) YoY; non-GAAP loss $155.9M ($1.47/share).

• August 22, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 7.01

  FDA cancels advisory committee meeting for Biohaven's troriluzole NDA; decision still Q4 2025

  FDA informed Biohaven on Aug 21, 2025 that an advisory committee meeting is no longer needed for troriluzole NDA review.

• August 15, 2025, 7:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Biohaven amends Knopp deal: royalty cut to mid-single digits, milestones reduced by >$800M

  Removed up to $562.5M in commercial sales milestones; reduced developmental/regulatory milestones from $575M to up to $210M.

• August 11, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Biohaven reports Q2 net loss $198M, cash $408.2M; OCD trial fails, VYGLXIA PDUFA in Q4 2025

  Net loss of $198.1M ($1.94 per share) vs $319.8M in Q2 2024; no revenue, clinical-stage biopharma.

• May 15, 2025, 7:59 PM ET regulatory materiality 0.75 neutral item 7.01item 9.01

  FDA extends Biohaven's troriluzole PDUFA date to 4Q 2025, plans advisory committee meeting

  FDA extends PDUFA date by 3 months to 4Q 2025 for troriluzole NDA for spinocerebellar ataxia (SCA).

• May 12, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Biohaven Q1 net loss $221.7M; announces $600M Oberland capital deal for troriluzole launch

  Net loss of $221.7M ($2.17 per share); non-GAAP adjusted net loss $166.8M ($1.64 per share).

• April 28, 2025, 7:59 PM ET debt materiality 0.85 positive item 1.01item 2.03item 7.01item 9.01

  Biohaven secures up to $600M non-dilutive financing from Oberland Capital for troriluzole development

  First tranche $250M funded at closing on or before April 30, 2025.

• March 3, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Biohaven reports $489M cash; FDA accepts troriluzole NDA with Priority Review for SCA

  Cash & securities totaled $489M as of Dec 31, 2024; R&D expenses Q4 2024 were $167.5M (vs $134.8M Q4 2023).

• November 12, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Biohaven reports Q3 net loss $160.3M; troriluzole SCA trial positive, NDA submission planned Q4 2024

  Net loss $160.3M ($1.70/sh) vs $102.6M loss ($1.50/sh) in Q3 2023; non-GAAP adj. net loss $164.1M ($1.74/sh).

• October 2, 2024, 7:59 PM ET other material materiality 0.70 neutral item 8.01item 9.01

  Biohaven completes $287.5M equity offering; 6.05M shares at $47.50

  Sold 6,052,631 common shares including full underwriter option at $47.50/share.

• September 23, 2024, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Biohaven troriluzole pivotal SCA study meets primary endpoint; NDA planned Q4 2024

  Troriluzole 200 mg once-daily met primary endpoint on f-SARA change from baseline at 3 years in all SCA genotypes.

• August 16, 2024, 7:59 PM ET other material materiality 0.65 neutral item 8.01item 9.01

  Biohaven expands at-the-market equity facility by $300M to total potential issuance

  Amendment No. 1 increases existing ATM capacity by $300M in common shares; sales via J.P. Morgan as manager.

• August 8, 2024, 7:59 PM ET earnings materiality 0.80 neutral item 2.02item 9.01

  Biohaven Q2 net loss $3.64/sh; pipeline highlights MoDE degrader data and FDA alignment for BHV-8000

  Net loss of $319.8M ($3.64/sh) in Q2 2024 vs $1.32/sh in Q2 2023; cash ~$440M.

• May 9, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  Biohaven Q1 net loss $179.5M ($2.20/shr) vs $70.5M loss a year ago; cash $287.6M plus $247.8M from April offering

  Net loss $179.5M ($2.20/shr); non-GAAP adjusted net loss $144.6M ($1.77/shr); both more than doubled vs Q1 2023.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.95 · Median 0.70 · Most common event other_material

7 positive 1 negative 20 neutral

source · BHVN on sec.gov